DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Ropinirole

Ropinirole

  • Apo-Ropinirole

    Apo-Ropinirole

  • Integrated Approaches for Genome-Wide Interrogation of The

    Integrated Approaches for Genome-Wide Interrogation of The

  • Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders

    Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders

  • Early Piribedil Monotherapy of Parkinson's Disease

    Early Piribedil Monotherapy of Parkinson's Disease

  • Augmentation Suffering and What Can Be Done About It

    Augmentation Suffering and What Can Be Done About It

  • Ropinirole 0.25 Mg Film-Coated Tablets

    Ropinirole 0.25 Mg Film-Coated Tablets

  • Dopamine Agonists 1

    Dopamine Agonists 1

  • DRUG TREATMENTS for Parkinson's

    DRUG TREATMENTS for Parkinson's

  • Product Monograph

    Product Monograph

  • Serotonin Syndrome in Stroke Patients

    Serotonin Syndrome in Stroke Patients

  • Neuromodulatory Neurotransmitters Influence LTP-Like Plasticity in Human Cortex: a Pharmaco-TMS Study

    Neuromodulatory Neurotransmitters Influence LTP-Like Plasticity in Human Cortex: a Pharmaco-TMS Study

  • Medications for Ataxia Symptoms

    Medications for Ataxia Symptoms

  • Pr SANDOZ MEMANTINE FCT Memantine Hydrochloride Tablets

    Pr SANDOZ MEMANTINE FCT Memantine Hydrochloride Tablets

  • Intranasal Drug Delivery in Neuropsychiatry: Focus on Intranasal Ketamine for Refractory Depression Chittaranjan Andrade, MD

    Intranasal Drug Delivery in Neuropsychiatry: Focus on Intranasal Ketamine for Refractory Depression Chittaranjan Andrade, MD

  • High-Risk Medications in the Elderly

    High-Risk Medications in the Elderly

  • Neupro, INN-Rotigotine

    Neupro, INN-Rotigotine

  • Ropinirole Immediate Release (IR) and Modified Release (MR) ESCA: for the Treatment of Parkinson’S Disease AREAS of RESPONSIBILITY for the SHARING of CARE

    Ropinirole Immediate Release (IR) and Modified Release (MR) ESCA: for the Treatment of Parkinson’S Disease AREAS of RESPONSIBILITY for the SHARING of CARE

  • Medication Guide for a Safe Recovery

    Medication Guide for a Safe Recovery

Top View
  • WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T
  • Ropinirole and Pramipexole, the New Agonists
  • Drug Repurposing Is a New Opportunity for Developing Drugs Against Neuropsychiatric Disorders
  • Impulse Control Disorders in Patients with Hyperpolactinemia Treated With
  • New Evidence for Reduced Leg Oxygen Levels in Restless Legs Syndrome Erik K
  • Clinical Characteristics of Pramipexole-Induced Peripheral Edema
  • Overview of Parkinson's Disease Treatment Options
  • REQUIP® (Ropinirole Hydrochloride) Tablets
  • Neupro, INN-Rotigotine
  • Ropinirole for Restless Legs Syndrome
  • Medicines-Management-December-2016-Newsletter
  • Bordeaux JJF Pharmacological Treatment of Parkinson's Disease
  • Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’S Disease
  • Therapeutic Class Overview Dopamine Agonists
  • Interactions with Entry & Integrase Inhibitors
  • Potential Herb-Drug Interactions Chart
  • Update: Treatments for Motor Symptoms of Parkinson's Disease
  • EMIT Drugs-Of-Abuse Urine Assays Cross-Reactivity List


© 2024 Docslib.org    Feedback